H12O-CNIO Lung Cancer Clinical Research Unit

Home | Research & Innovation | Scientific Programmes | Clinical Research Programme | H12O-CNIO Lung Cancer Clinical Research Unit

Luis Gonzaga Paz-Ares
Luis Gonzaga Paz-Ares Head of Clinical Research Unit
T +34 (+34) 917 328 000 (Ext )

Staff Scientists

  • María Teresa Agullo
  • Irene Ferrer
  • Itziar Otano
  • Beatriz Soldevilla

Clinical Investigator

  • Rocio García
  • María del Carmen Riesco
  • Rodrigo Sánchez
  • José Luis Solórzano
  • Álvaro Conrado Ucero
  • Jon Zugazagoitia

Post-Doctoral Fellows

  • María Cristina Cirauqui
  • Juan Manuel Coya
  • Gorka Ruiz de Garibay

Graduate Students

  • Carlos Carretero
  • María Inés Díaz
  • María del Carmen Fernández-Luna
  • Santiago García
  • David Gómez
  • Alberto Lens
  • Ángel Núñez
  • Javier Ramos
  • Beatriz Rubio
  • Alba Santos Ramos
  • Patricia Yagüe


  • Patricia Cozar
  • Laura García
  • Beatriz Gil
  • Patricia Llamas
  • Alicia Luengo
  • Patricia Plaza
  • Aranzazu Rosado
  • Rocío Suárez

Lung cancer continues to be the most frequent cause of cancer-related deaths worldwide. Our Unit focuses on the study of lung cancer, from fundamental research proposals to other more clinically oriented ones, always aiming to solve the problems of lung cancer patients. We are particularly interested in 2 research areas: the identification of new molecular biomarkers for diagnostic, prognostic, and predictive purposes; and the development of novel treatment strategies, including targeted therapies and immunotherapeutics. For example, we have contributed to elucidating the molecular determinants of EGFR or FGFR oncogenicity and have discovered biomarkers that may guide the efficacy of inhibitors of those receptors in lung cancer. We have continued to develop an extensive platform of patient-derived xenografts of non-small-cell and small cell lung cancers to test new therapeutic strategies. Finally, our Unit has extensive experience in taking new drugs to the clinic, as well as in conducting practice-changing phase II/III trials in the fields of personalised cancer care and immuno-oncology.